Jonathan Chang
Stock Analyst at Leerink Partners
(4.00)
# 1,738
Out of 4,534 analysts
553
Total ratings
37%
Success rate
6.6%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $9 | $3.79 | +137.47% | 1 | Jul 13, 2026 | |
| REPL Replimune Group | Reiterated: Hold | n/a | $10.51 | - | 49 | Jun 2, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $4.00 | - | 7 | Jun 2, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $180.39 | -18.51% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Maintained: Buy | $24 → $37 | $35.73 | +3.55% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $9.23 | +84.18% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $23.96 | +29.38% | 1 | Feb 3, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $15.94 | +50.56% | 19 | Jan 13, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $10.68 | +87.27% | 51 | Jan 13, 2026 | |
| ZLAB Zai Lab | Reiterated: Buy | $74 | $20.52 | +260.62% | 51 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $39 | $27.91 | +39.73% | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $7.47 | -19.68% | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $5 | $4.32 | +15.74% | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $0.11 → $0.09 | $0.037 | +143.24% | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $4.16 | +476.92% | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $34.05 | +76.21% | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $18.81 | +43.54% | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.0151 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $846.19 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $45.70 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0001 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.48 | n/a | 1 | Jun 1, 2022 |
Whitehawk Therapeutics
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $3.79
Upside: +137.47%
Replimune Group
Jun 2, 2026
Reiterated: Hold
Price Target: n/a
Current: $10.51
Upside: -
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.00
Upside: -
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $180.39
Upside: -18.51%
Nanobiotix
Apr 1, 2026
Maintained: Buy
Price Target: $24 → $37
Current: $35.73
Upside: +3.55%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $9.23
Upside: +84.18%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $23.96
Upside: +29.38%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $15.94
Upside: +50.56%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $10.68
Upside: +87.27%
Zai Lab
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $20.52
Upside: +260.62%
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $27.91
Upside: +39.73%
Oct 10, 2025
Maintained: Hold
Price Target: $8 → $6
Current: $7.47
Upside: -19.68%
Aug 18, 2025
Maintained: Buy
Price Target: $8 → $5
Current: $4.32
Upside: +15.74%
Aug 13, 2025
Maintained: Hold
Price Target: $0.11 → $0.09
Current: $0.037
Upside: +143.24%
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $4.16
Upside: +476.92%
Aug 11, 2025
Maintained: Buy
Price Target: $60
Current: $34.05
Upside: +76.21%
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $18.81
Upside: +43.54%
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.0151
Upside: n/a
Jun 30, 2023
Maintained: Buy
Price Target: n/a
Current: $846.19
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $45.70
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0001
Upside: n/a
Jun 1, 2022
Maintained: Buy
Price Target: n/a
Current: $4.48
Upside: n/a